Dr Siro Perez

Atisama Therapeutics advances RB042 into multiple ascending dose cohorts of Phase 1 Trial and appoints Bernard Coulie as Chair of the Board

Atisama Therapeutics reports its Phase 1 trial of RB042 advancing into multiple ascending dose cohorts, and appoints experienced biopharma executive Bernard Coulie as chair of its board.

Cheque-in: 8 startups gobbled up $572.12 million in funding this week

Weekly roundup of eight raises totalling $572.12 million, led by Firmus's $500 million round; RAGE Biotech, SunDrive, Number 8 Bio, Fabra, Keeyu, MyGig and Drone-Hand also funded, plus two RAGE Biotech executive appointments.

Also SmartCompany·Startup Daily·Startup Daily·Startup Daily·Startup Daily·Startup Daily·Business News Australia

RAGE Biotech raises $29 million for new lung disease treatment

Melbourne biotech RAGE Biotech has raised a $29 million Series A, with IP Group Australia and Hostplus leading, to fund human trials of its lung disease therapy; new executives were appointed.

Also Startup Daily

Australian collaboration and AU$10m investment fuels Ankere Therapeutics’ efforts to target inflammatory lung conditions

Biotech startup Ankere Therapeutics launches with a $10 million seed round co-led by IP Group and Brandon Capital to develop inflammatory lung disease therapies, building on research from Monash and UniSA scientists.

Also Brandon Capital portfolio·Startup Daily·@AuManufacturing